Degradable Hydrogels and Nanogels for the Delivery of Cells and Therapeutics

Degradable polymeric materials such as hydrogels are extensively utilized as delivery vehicles due to their biocompatibility and tunable properties. Encapsulating therapeutic agents inside hydrogels stabilizes the cargo by preventing degradation, extending circulation time, and also allows for targeted release and delivery. Due to their small size and tunable properties, nano-scale hydrogels, or nanogels, are frequently utilized to deliver therapeutics to areas difficult to reach, such as tumors and the cytoplasm, through traditional means. To control hydro- and nanogel function, degradable cross-links can be installed, allowing for cargo release in response to specific stimuli, such as hydrolysis or reduction. This dissertation offers three degradable strategies that can be applied to synthesize hydrogels and nanogels for the stabilization and release of therapeutic cargo. In the first example, mixed imine cross-linking chemistry was applied to synthesize poly(ethylene glycol) (PEG)-based hydrogels with tunable degradability to encapsulate and deliver cells. Time to degradation of the gels could be controlled from 24 hours to more than 7 days by varying the hydrazone structure and the ratio of hydrazone and oxime cross-links. Encapsulated cells exhibited high viability up to at least 7 days, suggesting this system may be useful for cell delivery applications.In the second example, disulfide cross-links were utilized to form redox-responsive nanogels comprised of trehalose copolymers. The synthesis of a methacrylate trehalose monomer (TrMA) was optimized, improving the overall yield from 14% to 42%. TrMA was subsequently copolymerized with pyridyl disulfide ethyl methacrylate (PDSMA) using free radical polymerization conditions to form copolymers with two monomer ratios (1:1 and 2:1) which were cross-linked with 1 kDa PEG-dithiol via disulfide exchange to form uniform nanogels approximately 9 nm in diameter. The addition of a cross-linker eliminated the need to add reducing agent to facilitate cross-linking and nanogel formation, making this approach ideal for the encapsulation of sensitive therapeutic agents.Next, PDSMA-co-TrMA nanogels were utilized to encapsulate, stabilize, and release glucagon, an unstable peptide hormone used to treat hypoglycemia. The amines on glucagon were modified with thiol groups while retaining their positive charges for reversible conjugation and cross-linking. Glucagon-nanogel conjugates were synthesized with >80% conjugation yield, and the reversible disulfide linkage between peptide and polymer allowed for efficient cargo release under mild reducing conditions. The nanogels stabilized glucagon against aggregation in solution up to five days as well as solubilized the peptide at neutral pH. In vitro bioactivity of the modified peptide was found to be comparable to native glucagon, suggesting this may be a promising formulation strategy for further in vivo study.Finally, a series of dual-enzyme responsive peptides was synthesized by masking the ε-amine of lysine with protease substrates. After unmasking the amine by enzymatic cleavage, a second enzyme was able to cleave at the C terminus of lysine, which was monitored colorimetrically. Three different dual-enzyme responsive peptides were prepared, (AcAAF)K-pNA, (AcFG)K-pNA, and (AcDEVD)K-pNA, for chymotrypsin, papain, and caspase 3 sensitivity, respectively, followed by trypsin sensitivity after cleavage by the first enzyme. This modular peptide design could be useful for selective drug delivery, studies on dual enzyme activity, as well as for diagnostic enzyme screening